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Background: The hematopoietic syndrome of the acute radiation syndrome (HSARS) is a life-threatening condition
in humans exposed to total body irradiation (TBI); no drugs are approved for treating this condition. Recombinant
human interleukin-12 (rHuIL-12) is being developed for HSARS mitigation under the FDA Animal Rule, where
efficacy is proven in an appropriate animal model and safety is demonstrated in humans.
Methods: In this blinded study, rhesus monkeys (9 animals/sex/dose group) were randomized to receive a single
subcutaneous injection of placebo (group 1) or rHuIL-12 at doses of 50, 100, 250, or 500 ng/kg (groups 2–5,
respectively), without antibiotics, fluids or blood transfusions, 24–25 hours after TBI (700 cGy).
Results: Survival rates at Day 60 were 11%, 33%, 39%, 39%, and 50% for groups 1–5, respectively (log rank
p < 0.05 for each dose vs. control). rHuIL-12 also significantly reduced the incidences of severe neutropenia, severe
thrombocytopenia, and sepsis (positive hemoculture). Additionally, bone marrow regeneration following TBI was
significantly greater in monkeys treated with rHuIL-12 than in controls.
Conclusions: Data from this study demonstrate that a single injection of rHuIL-12 delivered one day after TBI
can significantly increase survival and reduce radiation-induced hematopoietic toxicity and infections. These data
significantly advance development of rHuIL-12 toward approval under the Animal Rule as an effective stand-alone
medical countermeasure against the lethal effects of radiation exposure.
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Acute radiation syndrome (ARS) is a life-threatening ill-
ness caused by whole body or significant partial-body
exposure to radiation doses > 1 Gy over a short period of
time, as would occur in the event of a nuclear accident
or attack [1,2]. The pathophysiology of ARS is well
understood, and is similar across all mammals, involving
detrimental effects on the hematopoietic, gastrointes-
tinal, central nervous and cutaneous systems [3]. In the
hematopoietic subsyndrome of ARS (HSARS), toxicity is* Correspondence: basile@neumedicines.com
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article, unless otherwise stated.due to rapid bone marrow ablation [1,2], leading to pan-
cytopenia. HSARS ultimately results in death due to in-
fection and/or hemorrhage over the range of 2 weeks to
2 months, depending on the radiation exposure level
[1,2]. While the availability of a radiation medical coun-
termeasure (R-MCM) in the event of a large scale radi-
ation emergency is critical for saving lives, currently
no treatments are approved as R-MCMs by the US Food
and Drug Administration (FDA). Since early 1990s,
preclinical studies have demonstrated radioprotective
and/or radiomitigating properties of various cytokines
and cytokine cocktails, but their further clinical develop-
ment was hindered by adverse reactions [3-5]. A cocktailed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Survival of rhesus monkeys following exposure to
TBI and treatment 24 hours after TBI with either vehicle or
rHuIL-12. Kaplan-Meier plots of survival over the study period are
shown for each treatment group. Each dose group comprised 18
animals. Log rank p-values were 0.0305 0.0344, 0.0404, and 0.0265,
respectively for the 50 ng/kg, 100 ng/kg, 250 ng/kg and 500 ng/kg
dose groups vs. the vehicle-treated control group.
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ligand, thrombopoietin, and interleukin-3 with or with-
out a long-acting pegylated form of granulocyte-colony
stimulating factor (G-CSF) has been shown to improve
survival in murine and primate models of acute radi-
ation [6]. However, compared to the single agent ap-
proach, multicytokine combinations impose significant
difficulties from the drug development perspective as
well as logistical challenges for administration in the
mass casualty scenario.
Typical treatment guidelines for HSARS include short-
or long-term cytokine administration, depending on the
radiation exposure level [3]. While available cytokine
products support the growth of some individual cell
types (such as G-CSF for neutrophils) [1], they do not
consistently reduce overall mortality after TBI [7]. An
optimal R-MCM against HSARS would be able to regen-
erate all blood cell lineages, and, given the expected lo-
gistic impediments of a mass casualty scenario, should
be effective when administered hours to days after ex-
posure, preferably as a single dose, and in the absence of
intensive supportive care. These requirements are not
fulfilled by G-CSF, which affects only the granulopoietic
lineage, requires multiple daily administrations, and
improves survival only in combination with intensive,
trigger-based medical management [8]. Additionally, use
of G-CSF in the context of radiation exposure was associ-
ated with delayed adverse effects, such as long-standing
isolated thrombocytopenia [9] and lung toxicity [10].
We previously reported that a single administration of
recombinant human IL-12 (rHuIL-12) given 24–25 hours
after irradiation, in the absence of antibiotics, fluids or
blood products, improved survival in both a murine
HSARS model and in a proof-of-concept, open-label,
male-only study in non-human primates (NHP) [11].
These findings supported the further development of
rHuIL-12 as an R-MCM for HSARS under the FDA Ani-
mal Rule, where efficacy is proven in an appropriate ani-
mal model (eg, non-human primates [NHP]) and safety
is demonstrated in humans. Herein, we describe results
of a randomized, blinded, efficacy study of rHuIL-12 as
an R-MCM in a larger group of male and female rhesus
monkeys performed under Good Laboratory Practice
(GLP). This study advances rHuIL-12 towards approval
under the Animal Rule.
Results
Survival
Survival data are present in Figure 1. The administered
radiation dose corresponded to an approximate LD90/60
(2/18 animals in the control groups) under the condi-
tions of this experiment (no antibiotics, fluids or blood
transfusions). Of the 59 deaths that occurred among
rHuIL-12-treated animals, 58 occurred between Day 9and Day 24, which is consistent with previously observed
rates and timing of death due to HSARS in rhesus mon-
keys (CiToxLAB historical data), and one death occurred
at Day 33. The highest proportion of deaths occurred
between Day 11 and Day 21, with Day 14 being the peak
day of death for both control and rHuIL-12-treated
groups. The death rate was similar for males and fe-
males. All deaths, regardless of cause, were included in
the statistical analysis of survival, the primary efficacy
endpoint. As noted above, in the control group, 2 of
18 animals survived (11%, both males), while 33%
(3 males and 3 females), 39% (4 males and 3 females),
39% (4 males and 3 females), and 50% (5 males and 4
females) of animals survived in rHuIL-12 treated groups
2–5, respectively. Each rHuIL-12 treated group showed
a statistically significant increase in survival compared
with the control group (log rank test p < 0.05). Pair-wise
comparison between rHuIL-12-treated groups showed
no significant differences. Possible causes of unscheduled
death prior to day 60 were predominantly infection and
hemorrhage (Table 1).
Prodromal and clinical (manifest illness) observations
Vomiting and diarrhea occurred one or more times over
the course of the study in more than half of all animals,
with a higher incidence in the first few days following ra-
diation. Incidence of vomiting and diarrhea was similar
between the groups (Additional file 1: Table S1). De-
creased activity was observed primarily between Days 4
and 24, with the largest decrease in the control group
and smallest decrease in the group treated with highest
rHuIL-12 dose (500 ng/kg; Additional file 1: Figure S1).
Intermediate rHuIL-12 doses resulted in intermediate
Table 1 Causes of death at unscheduled euthanasia
rHuIL-12 dose group (ng/kg) All
Cause of death 0 (N = 16) 50 (N = 12) 100 (N = 11) 250 (N = 11) 500 (N = 9) (N = 59)
n (%) n (%) n (%) n (%) n (%)
Infection 13 (81.25) 12 (100) 10 (90.9) 10 (90.9) 8 (88.9) 53 (89.8)
Infection + hemorrhage 3 (18.75) 0 1 (9.1) 1 (9.1) 1 (11.1) 6 (10.2)
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verse trend with rHuIL-12 dose. Decreased appetite was
observed in two waves (Additional file 1: Figure S2): the
first, on Days 1 through 4, occurred as an immediate re-
action to irradiation; the second, on Days 10 through 34,
paralleled the period of highest rates of infection,
hemorrhage and death, as described below. During the
first wave, the degree of decrease in appetite was similar
between the control and rHuIL-12-treated groups, while
during the second wave, a trend toward positive effect of
rHuIL-12 was observed. Average body weight decreased
by 5 to 10% from baseline beginning 3 to 4 days after
irradiation and continuing up to Day 30, followed
by recovery and subsequent increases above baseline
(Additional file 1: Figure S3). The decrease in body weight
was similar in the control and rHuIL-12-treated groups.
Hematopoiesis
Blood counts for platelets, mean platelet volume, neu-
trophils, lymphocytes, and reticulocytes are presented in
Figure 2 A–E, respectively. Hematology blood samples
obtained at a pre-radiation time points were considered
to be baseline levels. Blood samples obtained at post-
radiation time points of 5, 10, 12, 14, 16 and 18 days
corresponded to the period of severe cytopenias seen in
the HSARS model. Additional samples obtained at days
30, 45 and 60 were used to evaluate whether levels
returned to baseline in surviving animals.
Platelets
Platelet nadirs occurred at day 12 or 14, depending on
the dosing group. Significant thrombocytopenia (<50 ×
109 /L) was present over days 10–15. The average plate-
let nadir in the control group (10.1 × 109 platelets/L)
was lower than that for each of the treated groups (12.1,
15.5, 12.7, and 18.6 × 109 platelets/L for groups
2–5, respectively). By day 18, initial recovery was ob-
served among survivors in all groups, with full recovery
observed by day 30. The proportions of blood samples
with severe thrombocytopenia (platelets <10 × 109 /L)
between Day 10 and 18 were 33% in the control group
and 34%, 20%, 22% and 12% in rHuIL-12 treated
groups 2–5, respectively. The pair-wise comparison of
the proportion of blood samples with severe thrombo-
cytopenia for rHuIL-12-treated animals and controls
was significant for the 500 ng/kg group (Fisher exact testp = 0.0073). Mean platelet volume was increased be-
tween day 14 and 18, likely due to the release of young
platelets from recovering bone marrow. Average peak
values were 8.64 fL in the control group compared with
9.21, 9.13, 9.56 and 9.17 fL in rHuIL-12 treated groups
2–5, respectively.
Neutrophils
Neutrophil nadirs occurred between days 10 and 14, de-
pending on dosing group. Severe neutropenia (<50 ×
106/L) occurred in 100% of animals in the control group
and in 88.9%, 77.8%, 83.3%, and 72.2% of animals in
rHuIL-12-treated groups 2–5, respectively. The average
neutrophil nadir of the control group (26 × 106 /L) was
lower than that for each of the treated groups (34, 54,
39, and 78 × 106/L in groups 2–5, respectively. Neutro-
phil recovery began by day 18 and baseline levels were
reached by day 30. The percentage of blood samples pre-
senting with severe neutropenia on days 10 to 18 was
67% in the control group compared to 46%, 35%, 46%
and 31% in groups 2–5, respectively (Fisher’s exact test
p = 0.0196, 0.0005, 0.0278, and < .0001, for comparison
of control and groups 2–5, respectively).
Lymphocytes
Lymphocyte nadirs occurred between days 10 and 16,
depending on dosing group. All groups showed severe
lymphopenia down to 7 – 10% of pre-radiation levels.
The average lymphocytes nadir in the control group
(0.143 × 109 /L) was lower than that for each of the
treated groups (0.163, 0.213, 0.220, 0.239 × 109/L for
groups 2–5, respectively). On Day 18, initial recovery
from the nadir was observed in all groups. By day 30,
group average levels ranged from 30% to near 60% of
the pre-radiation levels, and by days 45 and 60, counts
were in the normal range but remained slightly lower
than baseline levels. The difference in the lymphocyte
nadir between controls and animals treated with rHuIL-
12 was statistically significant in females treated at the
50, 250, and 500 ng/kg dose levels (Sidak adjusted t-test
p = 0.0443, 0.0103, and 0.0211, respectively).
Red blood cells and reticulocytes
The red blood cells nadir occurred on Days 16–18, and
represented a 37% reduction from baseline. Red blood




Figure 2 Blood counts over time in rhesus monkeys exposed to lethal TBI and treated 24 hours after TBI with either vehicle or
rHuIL-12 (Average ± SEM). A) platelets; B) mean platelet volume; C) neutrophils; D) lymphocytes; E) reticulocytes; F) red blood cells. Normal
ranges are as follows: platelets, 252 to 612 × 109/L; mean platelet volume, 6.3 to 9.4 × 109/L; neutrophils, 1.21 to 10.29 × 109/L; lymphocytes,
1.85 to 8.71 × 109/L; reticulocytes, 29.9 to 103.9 × 109/L; red blood cells, 4.95 to 6.94 × 1012/L.
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the control group and 8.7 × 109/L, 12.1 × 109/L, 9.1 ×
109/L, and 9.8 × 109/L in rHuIL-12-treated groups 2–5,
respectively, suggesting a stimulatory effect of rHuIL-12
on erythropoiesis. However, the differences did not reach
statistical significance.
Relationships between hematopoietic recovery and
survival
Mean lymphocyte, platelet, neutrophil, and reticulocyte
counts were higher in survivors than in decedents
among the rHuIL-12 treated animals (in Additional
file 1: Figure S4). Average platelet, neutrophil, and re-
ticulocyte counts were higher in the survivors treated
with rHuIL-12- than in survivors treated with vehicle
control (in Additional file 1: Figure S4).
Febrile neutropenia
A total of 15 animals (8 males; 7 females) had febrile
neutropenia, and most (10/15) had been treated at the
two highest dose levels (group 4, 250 ng/kg and group 5,
500 ng/kg) of rHuIL-12. Ten of the 15 animals with fe-
brile neutropenia had a positive hemoculture; the most
common bacteria identified were Escherichia coli and
Staphylococcus aureus. Duration of febrile neutropenia
was 1 day in all 15 affected animals and resulted in death
on the same or next day in 12 of the 15 animals. Three
of the 15 animals survived to Day 60 (1 in group 4 and 2




In the control group hemoculture positivity was 86%,
compared to 65%, 65%, 47% and 44% in rHuIL-12-
treated groups 2–5, respectively. The difference was sta-
tistically significant for the two highest doses (Fisher’s
exact test p = 0.0072 for each group). The decrease inTable 2 Macroscopic organ hemorrhage score and organ infe
Dose (ng/kg) Total hemorrhage scorea
0 8.4 ± 1.6
50 5.1 ± 0.63
100 6.6 ± 0.73
250 5.0 ± 1.0
500 5.8 ± 1.1
aHemorrhage was assessed on necropsy of found dead or preterminally euthanized
following tissues were included in calculating the mean hemorrhage scores present
heart, brain, kidneys, liver, lungs, urinary bladder). Hemorrhage score was defined a
hemorrhage(s); 3 = moderate hemorrhage(s); 4 = marked hemorrhage(s); and 5 = sev
mean score for each treatment group was calculated.
bThe following tissues were included in calculating the GI tract hemorrhage score: s
cFor infection score determination, organ samples were collected on necropsy and
heart, kidney, liver, both lungs, and spleen. Bacterial growth was scored for each or
mean score for each treatment group was calculated.the prevalence of infection was observed for both gram-
negative and gram-positive bacteria. Bacteriological ana-
lysis of heart, kidney, liver, both lungs, brain and spleen
performed at necropsy for all animals revealed a lower
mean bacterial growth score in rHuIL-12-treated ani-
mals compared to that of controls (Table 2).
Escherichia coli and Staphylococcus aureus were the
most frequent isolates from organs and hemoculture.
Among animals that underwent unscheduled euthanasia,
12 of 16 (75%) control animals had organ cultures that
were positive for Escherichia coli compared with 66.7%,
63.6%, 72.7% and 55.6% of animals in rHuIL-12 treated
groups 2–5, respectively. Similarly, 10 of the 16 (62.5%)
control animals that underwent unscheduled euthanasia
had organ cultures that were positive for Staphylococcus
aureus compared with 50.0%, 54.5%, 54.5% and 44.4% of
animals in rHuIL-12 treated groups 2–5, respectively.
Pathology
Macroscopic evaluation of hemorrhage
Overall group mean hemorrhage scores for all organs, as
well as a separate score for the gastrointestinal system,
are shown in Table 2. Although the mean scores were
higher in the control group than in all rHuIL-12-treated
groups, the differences did not reach statistical signifi-
cance, likely due to substantial organ to organ and ani-
mal to animal variation. Notably, the proportions of
animals that had hemorrhage scores ≥ 4 in at least one
organ were higher in the control group than in the
groups treated with rHuIL-12, and brain hemorrhage
was found only in 2 animals in the control group.
Microscopic evaluation
A wide range of microscopic findings were observed in
numerous organs/tissues from monkeys who died or
were euthanized before day 60. Microscopically, TBI-
related hemorrhage was noted in numerous organs.
Other microscopic findings related to TBI were noted inction score per animal (average ± SEM)
GI tract hemorrhage scoreb Total infection scorec
5.6 ± 1.1.4 12.8 ± 2.2
3.2 ± 0.75 12.3 ± 3.4
4.5 ± 0.90 10.6 ± 3.7
3.1 ± 0.78 8.8 ± 3.1
3.7 ± 0.70 8.2 ± 3.3
animals by a pathologist blinded to the therapy group assignment. The
ed in this table: stomach, ileum, jejunum, duodenum, colon, cecum, rectum,
s follows: 0 = absence of hemorrhage; 1 =minimal hemorrhage(s); 2 = slight
ere hemorrhage(s). In each animal scores for all organs were summed, then
tomach, ileum, jejunum, duodenum, colon, cecum, and rectum.
cultured (animals found dead excluded from the analysis), including brain,
gan (from 0 to 4). In each animal scores for all organs were summed, then
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and kidney. Microscopic changes in many organs includ-
ing small and large intestines, heart, liver, lungs, mesen-
teric lymph node, and spleen were considered to be
predominantly secondary to episodes of bacteremia/
septicemia. In animals surviving to day 60, microscopic
findings related to irradiation were noted in lymphoid
tissue, gastrointestinal tract, kidney, and bone marrow.
Except the hemorrhage reduction trend in the rHuIL-
12 treated animals, there were no substantial differences
between the characteristics or the incidence and/or se-
verity of the macroscopic and microscopic findings in
the control group compared to the rHuIL-12-treated
groups, among both pre-terminally euthanized animals,
animals that died, and surviving animals euthanized on
day 60.Pharmacokinetics, pharmacodynamics and bone marrow
assessment
In a companion study, a separate cohort of animals
(2 per gender per group) was exposed to the same radi-
ation level as in the survival study and treated with the
same dose levels of rHuIL-12. Blood samples were col-
lected at sequential time points from baseline through
day 11 and analyzed for rHuIL-12, IFN-γ, IL-18, and
IP-10. A dose dependent increase in rHuIL-12 exposure
as well as increased plasma levels of IFN-γ, IL-18, and
IP-10 were observed (Table 3).
All animals were sacrificed at Day 12, which repre-
sented the day of estimated maximal bone marrow
suppression based on the timing of nadir of blood
cell counts in the previous study. Histological analysis
of bone marrow showed severe hypocellularity with
pockets of regeneration (Figure 3A). Quantitation of the
number of regeneration islands, the total area of the re-












0 BLQ BLQ 150.20 (NR) 24868.80 (NR)
50 14.65 (4.75) 190.61 (90.51) 257.73 (120.42) 6239.20 (5395.40)
100 39.03
(15.85)


















All data are means (standard deviations).
Abbreviations: BLQ-Below the limit of quantitation; AUC, area under the concentrati
due to < 3 animals contributing data.each animal was performed in a blinded analysis. Both
the number and the area of the regenerative islands were
higher in the rHuIL-12-treated groups compared with
control, and the increases were similar across the
rHuIL-12-treated groups (Figures 3 B-C). The difference
for both parameters reached statistical significance for
animal in group 5 (t-test p <0.01 and p <0.05 for number
and area of islands of regeneration, respectively), as well
as in a pooled comparison (all treated groups versus
control group; p = 0.0272 and p = 0.0311 for number and
area of islands of regeneration, respectively). Import-
antly, the number of megakaryocytes was also higher for
all rHuIL-12 treated groups relative to control, but the
differences were not statistically significant (Figures 3D).Discussion
The data from this randomized, blinded, placebo-con-
trolled study demonstrate a positive and significant ef-
fect of a single, subcutaneous injection of rHuIL-12,
over a 10-fold dose range, on survival following lethal
TBI (700 cGy; LD90/60) in the rhesus monkey model of
HSARS. The animal model used in this study has been
validated at CiToxLAB North America as an established
model of human HSARS, based on the occurrence of
similar hematologic effects, infection and hemorrhage
following TBI as reported for humans [8,11]. Compared
with other studies using a similar NHP model [8], our
study did not include supportive care in the form of an-
tibiotics, blood products and intravenous fluids, and
therefore allows for a clearer demonstration of the ef-
fects of mitigating treatments and affords greater rele-
vance for the mass casualty scenarios following a nuclear
attack or accident, where intensive, hospital-based care
would be significantly delayed and/or limited.
The current study, conducted under the FDA Animal
















































on vs. time curve; 0-t, time 0 to time of assessment; hr, hour; NR, not reported
Figure 3 (See legend on next page.)
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Figure 3 Identification of Bone Marrow Regeneration Islands. (A) Histopathological identification of regenerating bone marrow. Clusters
of cells appearing in otherwise ablated bone marrow were scored as one regenerating island. Left panel, ablated bone marrow; middle panel,
regenerating bone marrow; right panel, non-irradiated bone marrow. (Olympus BX41 compound microscope; Infinity Analyze software v5.0,
magnification: 10×). (B) Quantification of number of islands of regeneration for individual treatment groups (left panel, p < 0.01 for 500 ng/kg
group vs. control) and the combined rHUIL-12-treated groups vs. vehicle-treated control (right panel, p < 0.05). (C) Quantification of area of
regeneration for individual treatment groups (left panel, p < 0.05 for 50 and 500 ng/kg groups vs. control) and the combined rHuIL-12-treated
groups vs. vehicle-treated control (right panel, p < 0.05). (D) Quantification of megakaryocytes for individual treatment groups (left panel) and
the combined rHuIL-12-treated groups vs. vehicle-treated control (right panel).
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[11], as it was blinded, randomized, and GLP compliant,
and involved more than twice the number of animals.
The mechanism by which IL-12 rescues animals fol-
lowing TBI involves the multiple effects of IL-12 on
hematopoieses and immune function. Radiation-induced
bone marrow suppression was mitigated by rHuIL-12:
animals treated with rHuIL-12 showed statistically
significant reductions in the occurrence of severe neu-
tropenia and severe thrombocytopenia, as well as attenu-
ated nadirs for lymphocytes, neutrophils, platelets, and
reticulocytes. Further, the increase, relative to controls,
in mean platelet volume among animals treated with
rHuIL-12 suggests that rHuIL-12 promoted release of
newly formed platelets from the bone marrow. Quantita-
tive analysis of the number and size of bone marrow
regenerative pockets supports the conclusion that rHu
IL-12 alone stimulates hematopoiesis, allowing for re-
covery of all major blood cell components.
Our in vivo observation that rHuIL-12 induced recov-
ery of multiple hematopoietic lineages is consistent
with previous reports in which IL-12 stimulated growth
of hematopoietic stem cells and progenitors in vitro
[12-14], and prevented radiation-induced death of
hematopoietic stem cells in vivo in a murine model of
HSARS [15]. This multilineage hematopoietic effect is
also consistent with our previous findings in studies of
tumor-bearing mice [16] and with our observation that
IL-12 receptors are present on hematopoietic stem cells
[11]. The observations that rHuIL-12 increased propor-
tion of animals with higher blood counts, and higher
blood counts were associated with survival, support the
conclusion that rHuIL-12 improved survival by mediat-
ing early regeneration of multilineage bone marrow
hematopoiesis, as compared to control.
Decrease of lymphocyte counts below 0.25 × 109/L has
been established as a marker of irreparable lethal bone
marrow damage in a large database of human victims of
acute radiation [17]. As such, it is important to note that
in our study, the average lymphocyte nadir was 0.09 ×
109/L among decedents in the control group, 0.14 ×
109/L among decedents in the rHu-IL12-treated groups,
and 0.27 × 109/L among survivors in all groups. These
findings further support the validity of our animal modelas an accurate representation of human HSARS and its
ability to predict effectiveness in humans exposed to le-
thal radiation.
Consistent with the reduction in severe neutropenia
and lymphopenia, the incidence of blood culture positivity
for infection was significantly lower in rHuIL-12-
treated groups 4 and 5 (47% and 44%, respectively) com-
pared with than in the control group (86%). These data
demonstrate that rHuIL-12, administered 24 hours after
TBI, in the absence of antibiotics, decreased infectivity
of broad-spectrum bacteria. These effects are consistent
with and are likely due to the well-known multiple
stimulatory effects of IL-12 on innate and adaptive im-
munity [18]. On critical days 14–18 associated with
deadly infections in this HSARS NHP model, the aver-
age lymphocyte counts in rHuIL-12 treated groups were
higher than in control animals. The improvement of
lymphocyte counts in this critical period may have pro-
vided enhancement of the T-cell-mediated immunity
and B-cell antibody-mediated immunity (B cells)
defense system, thereby contributing to higher survival
in the treated groups as compared to the placebo group.
Previous studies in mice have shown that during the early
stages following exposure to lethal radiation, type 1
T-helper cell (Th1) function is reduced due to the sup-
pression of endogenous IL-12 secretion from antigen
presenting cells [19,20]. IL-12 administration may alle-
viate the radiation-induced impairment of Th1 function
by promoting proliferation and activation of the NK
cells, macrophages, and dendritic cells [21], which can
be damaged by radiation [22]. Here we demonstrated
that in irradiated monkeys rHuIL-12 increases plasma
levels of IFN-γ, the hallmark of NK cell activation, as
well as IL-18, and IP-10, similarly as we observed previ-
ously in non-irradiated monkeys [11]. The tri-
directional cross-talk between NK, macrophages and
dendritic cells further promotes their maturation [23],
leading to the restoration of Th1 function and the estab-
lishment of early immune competence following TBI
[11]. Further, continuous production of endogenous IL-
12 from pathogen-activated dendritic cells serves as a
positive feedback loop and plays a key role in sustaining
the initial response to exogenous IL-12 [24]. Taken to-
gether, these IL-12 generated immune-mediated effects
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observed in this study.
Consistent with the reduction in severe thrombocyto-
penia, rHuIL-12 treatment in this study was associated
with lower severity of hemorrhage for animals that died
or were euthanized prior to the scheduled termination
on Day 60. In support of our finding that treatment
with rHuIL-12 was associated with reduced severe
thrombocytopenia and hemorrhage, we recently re-
ported that hematopoietic stem cells, megakaryocytes
and osteoblasts in the bone marrow express the IL-12
receptor β2 subunit (IL-12Rβ2) [11], which is primary
subunit for IL-12 signaling [25]. The presence of IL-
12Rβ2 receptors on these key bone marrow cells suggest
that through its receptors, rHuIL-12 may promote pro-
liferation and differentiation of the surviving stem cells
and megakaryocytes following exposure to lethal radi-
ation, thereby enhancing platelets regeneration and re-
ducing severe thrombocytopenia. Indeed, quantitative
analysis of the bone marrow in our current companion
study showed that relative to controls, rHuIL-12 treated
groups had higher numbers of megakaryocytes. The abil-
ity of rHuIL-12 to facilitate regeneration of platelets may
be of clinical importance in indications other than
HSARS mitigation, such as cancer, as there is currently
no available drug that can facilitate platelet recovery fol-
lowing myelosuppressive therapies.
While leucocyte growth factors are recommended for
use in victims of radiation, they are not approved by
FDA for this indication. One published study of radi-
ation mitigation in NHP demonstrated improved sur-
vival following exposure to lethal radiation for animals
treated with rHuG-CSF in combination with intensive,
trigger-based medical management (antibiotics, intraven-
ous blood product transfusions, intravenous fluid re-
placement) compared with that of control animals that
received only the medical management [8]. We recently
completed a randomized, blinded study comparing a sin-
gle injection of rHuIL-12 or vehicle with 18 injections of
rHuG-CSF in the NHP model without supportive care.
Survival analysis confirmed superior survival in the
rHuIL-12-treated group vs. both the control group and a
G-CSF-treated group. Notably, G-CSF did not provide
any survival benefit compared to control (Gluzman-Pol-
torak et al., submitted for publication).
In parallel to the animal efficacy studies, the safety and
tolerability of rHuIL-12 has been examined in normal
healthy subjects per the Animal Rule. A first in human
(FIH) study was conducted to determine the safe and
well-tolerated doses of rHuIL-12 via dose escalation
(at doses ranging from 2 to 20 μg). The FIH study was
followed by a phase 1b expansion study at the highest
safe and well-tolerated dose from the FIH study of 12 μg
(Gokhale et al., accepted for publication). The 12 μg unithuman dose for a 70 kg adult can be converted to
171 ng/kg rhesus monkey dose using a weight based
conversion and this dose is within the efficacious dose
range as determined in our rhesus monkeys studies.
Conclusion
In summary, this randomized, placebo-controlled, blin-
ded study has demonstrated that rHuIL-12 is an effective
frontline radiomitigator due its ability to increase sur-
vival and regenerate the hematopoietic system when ad-
ministered as a single, low dose without supportive
antibiotics, fluids or blood products 24 hours following
exposure to lethal radiation. Translation of the effica-
cious and safe dose from an animal model to humans is
a significant challenge for any drug development pro-
gram under the Animal Rule. Thus, our finding that sta-
tistically significant increases in survival can be achieved
over a ten-fold effective dose range of rHuIL-12 in the




All procedures were reviewed and approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of
CiToxLAB Research, Inc.
Animals
Studies were conducted in compliance with the Good
Laboratory Practice (21 CFR Part 58) at CitoxLAB North
America (a Contract Research Organization, Montreal,
Quebec, Canada). Rhesus monkeys (Macaca mulatta)
were obtained from the Yongfu County Xingui Wild An-
imals Raising Ltd., China. Monkeys (3 to 5 years old, and
3.0 to 5.7 kg at the start of treatment) were housed indi-
vidually and acclimated for ≥ 5 weeks prior to irradiation.
Harlan Teklad Certified Hi-Fiber Primate Diet #7195C
(Harlan Laboratories, Indianapolis, Indiana) was provided
twice daily.
Experiment design
The dose of 700 cGy (60 cGy/minute from a Theratron
1000 Co60 source [Best Theratronics; Ottawa, Ontario,
Canada]) was based on available historical data from
CiToxLAB North America. TBI was conducted with ani-
mals in a vertical position, as described previously [11].
For homogenous dose distribution, the first half-dose
was delivered anteroposterior and the second half-dose
was delivered posteroanterior. Dosimetry was verified to
be within 10% of prescribed dose using nanodot chips
(Landauer, Inc., Glenwood, Illinois, USA) positioned on
the front and back of each animal.
In the main study, male and female animals (45 each;
9 animals per sex per dose group) were randomized,
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ical grade rHuIL-12 administered by SC injection be-
tween the scapulas approximately 24–25 hours following
TBI: vehicle control (Group 1), 50 ng/kg (Group 2),
100 ng/kg (Group 3), 250 ng/kg (Group 4), or 500 ng/kg
(Group 5). The concentration of the test item in each
dosing sample was verified by Intertek Pharmaceutical
Services (San Diego, CA) using the Quantikine® Human
IL-12 ELISA Kit (R&D Systems Inc., Minneapolis, USA).
The pathologist and study staff other than the study
team leader and those involved with irradiation were
blinded. Specifically, animal care and euthanasia deci-
sions were made by the blinded personnel.
Symptomatic care
The following products were permitted as symptomatic
care: buprenorphine (0.01-0.015 mg/kg/dose BID or TID,
SC) for pain; bupivacaine (0.25%) topically for manage-
ment of mouth ulcers; Pepto-Bismol for management
of diarrhea; snacks or supplements (Rhesus Liquid Diet
[BIO-SERV; Frenchtown, New Jersey], Ensure® [Abbott
Laboratories, Abbott Park, Illinois, USA], vegetables,
juices, or crushed cookies with banana) for anorexia; top-
ical hydrotherapy and/or iodine 1% for wounds.
Assessments
Decreases in appetite (based on food intake) and phys-
ical activity were recorded daily and scored as follows:
1 = slight; 2 =moderate; and 3 = severe. A detailed phys-
ical examination was performed prior to rHuIL-12
dosing and twice weekly thereafter. Body temperature
(auricular) was taken prior to irradiation and on Days
3–10, 12, 14, 16, 18, 30, 45, and 60, or when clinically
justified. Blood sampling (0.5 mL) for peripheral blood
counts was performed prior to irradiation and at Days 5,
10, 12, 14, 16, 18, 30, 45, and 60. Blood was collected for
hemoculture in cases of febrile neutropenia (absolute
neutrophil count <0.05 109/L together with rectal body
temperature ≥104º F/40.0°C) and at necropsy.
Terminal procedure
Animals were euthanized prior to Day 60 if any of the
following criteria were observed: respiratory distress;
complete anorexia for 3 day; loss of > 20% of initial body
weight over a 3 day period; severely decreased activity
level (recumbent during an entire observation period or
unresponsiveness to touch); acute loss of > 20% esti-
mated blood volume; generalized seizure activity; abnor-
mal appearance (posture, rough coat, head down,
exudates around eyes and nose, pallor, tucked abdomen
and clinical appearance) associated with abnormal vital
signs: severe dehydration with hypothermia (decreasing
rectal temperature reaching <34.6ºC and severely decreased
activity level) or hyperthermia (temperature >40.1°C andseverely decreased activity level). Euthanasia decisions were
made by a team of technicians and veterinarians blinded to
the animal group assignment. Surviving animals were eu-
thanized at Day 60 following TBI.
Necropsy comprised an external macroscopic examin-
ation, a detailed internal examination, evaluation of
organ weights and gross pathology, and collection of tis-
sues for histopathology. Presence of hemorrhage was
scored for major organs as follows: 0 = absence; 1 = min-
imal; 2 = slight; 3 =moderate; 4 =marked; 5 = severe. For
histological examination, tissues were embedded in par-
affin, sectioned and stained with hematoxylin and eosin-
phloxin (H & E).
Microbiological analysis was conducted on brain, heart,
kidney, liver, both lungs, and spleen. Bacterial growth was
scored (0 to 4) for each organ. The total score was
summed for each animal; the mean score was calculated
for each treatment group.
Pharmacokinetics and pharmacodynamics of rHuIL-12
and bone marrow histopathology in irradiated rhesus
monkeys
An evaluation of pharmacokinetics and pharmacodyna-
mics of rHuIL-12 in irradiated rhesus monkeys was con-
ducted using separate animals randomized to the same
doses of rHuIL-12 as in the survival cohort (2 per sex
per group). Blood samples from animals treated with SC
rHuIL-12 or placebo were collected at the following time
points: pretreatment (approximately 2 weeks prior to ir-
radiation), 24 hours after irradiation immediately before
rHuIL-12 dosing, and at 1, 3, 5, 8, 12, 24, 48, 72, 96, 120,
144, 240, and 264 hours after rHuIL-12 dosing. The con-
centrations of rHuIL-12 and IFN- γ in monkey plasma
were determined by validated GLP ELISA methods at
Intertek ALTA Analytical Laboratory (San Diego, CA).
rHuIL-12 was measured using the Human IL-12 HS
ELISA kit (catalog # PHS120, HS120, or SS120 or
equivalent; R&D Systems). The lower limit of quantita-
tion was 3.5 pg/mL in 100% monkey plasma. IFN-γ was
measured using the Monkey IFN-γ ELISA kit (catalog #
3420 M-1H-20, or equivalent; Mabtech, Inc., Marie-
mont, OH ). The lower limit of quantitation was 7.5 pg/
mL in 100% monkey plasma. Interleukin-18 (IL-18) and
interferon γ-induced protein (IP-10) levels were deter-
mined using non-GLP qualified ELISA methods at
Neumedicines, Inc. IL-18 was assayed using the MBL
International Corporation Human IL-18 ELISA (R&D
Systems, Minneapolis, MN). The lower limit of quantita-
tion was 120 pg/mL in 100% monkey plasma. IP-10
concentrations were determined in plasma using a
Quantikine Human CXCL10/IP-10 ELISA (R&D Sys-
tems, Minneapolis, MN). The lower limit of quantitation
was 15 pg/mL in 100% monkey plasma. Standard non-
compartmental analyses were performed using Phoenix™
Gluzman-Poltorak et al. Journal of Hematology & Oncology 2014, 7:31 Page 11 of 12
http://www.jhoonline.org/content/7/1/31WinNonlin® Version 6.3 (WinNonlin; Pharsight Corpor-
ation, Mountain View, CA).
The separate cohort animals were euthanized on Day
12 after TBI, except one animal that underwent un-
scheduled euthanasia on Day 11. All animals were in-
cluded in the bone marrow analysis. Two H & E femur
sections for each animal were scanned on an Olympus
BX41 compound microscope. Images of approximately
40 fields of view encompassing each femur section in its
entirety were acquired on Infinity Analyze software v5.0
at a magnification of 10×. The number of bone marrow
regeneration islands was determined by visual quantifi-
cation in each field of view in each section. The total
area of bone marrow regeneration was determined using
ImageJ software, version 1.46. The mean number of re-
generation islands and mean area of regeneration from
two sections per animal were used in the statistical ana-
lyses. The number of megakaryocytes was determined
visually in each femur section.
Statistical analysis
All statistical comparisons were conducted for sex and
for the entire study population. Survival functions were
estimated using the Kaplan-Meier product-limit method
applied on daily intervals. The control group was com-
pared to each of the other treated groups using the
Mantel log-rank test. Predefined GLP survival analysis
was performed at CiToxLAB.
Group comparisons for incidences of severe neutropenia
(defined as neutrophil count < 0.05 × 109/L), severe throm-
bocytopenia (defined as platelet count < 10 × 109/L), and
hemoculture positivity (sepsis) were performed using Fisher
Exact test. If the overall comparison was significant (p ≤
0.05), pair-wise comparisons between control group and
each dosing group was done using the Fisher Exact test.
Group means for bone marrow regeneration data
(number and area of regeneration islands) were com-
pared by a one-tailed t test using the statistical software
program Prism version 6 (GraphPad, San Diego, CA).
Differences with p <0.05 were considered significant.
Additional file
Additional file 1: Table 1. Percentage of animals presenting with
selected early clinical signs on one or more days following TBI. Figure 1.
Decrease in physical activity. Figure 2. Decrease in appetite score.
Figure 3. Body weight over time. Figure 4. Blood counts over time in
surviving vs. non-surviving rhesus monkeys exposed to lethal TBI and treated
24 hours after TBI with either vehicle or rHuIL-12 (Average ± SEM).
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